The conversation discusses alternatives to Dr. B's hair loss treatments, specifically mentioning Minoxidil, Finasteride, and RU58841. A user notes a price discrepancy on a website.
A 32-year-old male is experiencing hair loss despite using 0.5 mg Dutasteride and 2.5 mg Minoxidil daily, along with previous hair transplants and Finasteride use. He is considering increasing Dutasteride dosage and exploring other treatments like RU58841, but remains skeptical about their effectiveness and concerned about costs.
The user experienced reduced effectiveness of minoxidil after consistent use, despite using dutasteride to maintain hair. They are considering alternatives like microneedling and exploring options like hair transplants due to dissatisfaction with current hair density.
A gel of keratin microspheres promotes hair follicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
Trans women discuss using finasteride and dutasteride for hair loss and whether to continue after testosterone suppression. One user reduced dutasteride dosage after achieving undetectable testosterone levels.
The conversation discusses hair loss treatments, specifically using a Dermaroller, Minoxidil, and RU58841 for two months. The user shared progress pictures showing the results of these treatments.
RU58841 slowed hair loss for a DUPA sufferer after other treatments like finasteride, dutasteride, and minoxidil failed. Some users reported side effects with RU58841, while others did not experience any.
KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.
The user shared progress pictures and discussed using oral and topical Minoxidil, microneedling, recently starting finasteride, multivitamins, vitamin D3, vitamin K, tretinoin, and ketoconazole for hair loss. The conversation focuses on the effectiveness of these treatments.
TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.
A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.
The user is frustrated with the lack of visible hair regrowth after 7-8 months of using finasteride and minoxidil, despite initial vellus hair growth. Others suggest patience, switching to oral minoxidil, or using additional treatments like dermastamping, microneedling, and red light therapy.
KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.
In this conversation, people discussed how Minoxidil and Finasteride can be toxic to cats if ingested. It was highlighted that even when being careful with application, there is still a risk of poisoning due to the potential for contact between fur/hair and the substances.
Using a combination of finasteride, minoxidil, dermarolling, and RU58841 to treat hair loss. Participants discussed the time commitment required for treatment and the effectiveness of different dosages.
User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.
Some users maintained hair gains after stopping microneedling while continuing minoxidil and finasteride, while others saw no improvement or experienced hair breakage. One user switched to oral minoxidil and continued finasteride and dutasteride after seeing no results from microneedling.
Exploring potential treatments for hair loss, with the focus being on comparing RU58841 and Pyrilutamide. Finasteride, Dutasteride, oral Minoxidil, microneedling, topical Minoxidil, Biotin, Zinc, Vitamin D and Nizoral are also discussed as part of a treatment stack.
A user's progress with hair loss treatments, including minoxidil, microneedling, nizoral 2%, finasteride 0.5mg/day and 0.5mg/ml per day in minoxidil, as well as RU58841 purchased from Anagen Inc., which allowed the user to go outside without a hat or cap for two years.
Despite using dutasteride, RU58841, minoxidil, and ketoconazole for years, the user continues to experience severe hair loss and thinning. They seek advice after multiple dermatologists confirmed androgenetic alopecia (AGA) but offered no effective solutions.
The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It suggests that affordable genetic therapy could be the ultimate solution.
The user had a hair transplant at Vera Clinic Istanbul and is using 1mg Finasteride six times a week, 0.5mg Dutasteride once a week, and topical Minoxidil daily. They wash out the Minoxidil each morning and are happy with the results, noting the importance of medication to prevent further hair loss.
A female user's six-month progress with only minoxidil and ketoconazole, including their experiences before and after using the treatments. They also discussed the differences between male and female hair loss and suggested that meds may offer more progress, though some results can be had without them.
Finasteride may affect male offspring's fertility and hormonal balance, with debates on whether to discontinue use before conception. Some users report no issues, while others highlight the high doses used in rat studies.
The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.
A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.